Lipoblastoma

Summary

Lipoblastoma (MONDO:0016611) is a disease. A subtype of benign soft tissue neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lipoblastoma
Mondo ID	MONDO:0016611
MeSH	D062689
Orphanet	247762
ICD-11	581420938
NCIT	C27483
SNOMED CT	400102008
UMLS	C1260965
MedGen	220362
GARD	0012015
Is cancer (heuristic)	no

Also known as: embryonic lipoma · fetal lipoma · foetal lipoma · infantile lipoma

Disease family

This is a subtype of benign soft tissue neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign connective and soft tissue neoplasm › benign soft tissue neoplasm › lipoblastoma

Related subtypes (9): endobronchial lipoma, endometrial stromal nodule, fibroosseous pseudotumor of the digits, angiomyxoma, soft tissue chondroma, infantile myofibromatosis, benign PEComa, benign synovial neoplasm, myxoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.